浩欧博股价涨5.2%，招商基金旗下1只基金重仓，持有1.07万股浮盈赚取8.28万元

Group 1 - The core point of the news is that Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a stock price increase of 5.2%, reaching 156.91 CNY per share, with a total market capitalization of 9.961 billion CNY [1] - The company specializes in the research, production, and sales of in vitro diagnostic reagents, with 89.46% of its revenue coming from reagent sales [1] - The company was founded on June 8, 2009, and went public on January 13, 2021 [1] Group 2 - According to data, a fund under China Merchants Fund holds Haobio as its ninth largest position, with a total of 10,700 shares, representing 4.31% of the fund's net value [2] - The fund, named China Merchants Growth Pioneer Stock A, has seen a year-to-date return of 32.24% and a one-year return of 20.72% [2] - The fund manager, Mei Mei, has been in the position for 280 days, with the best return during this period being 37.41% [2]